Feb 3 screen showed bullish expansion across trend and SMA crossovers. In 50-200 SMA $SJ +21.8% vol +114%, $CBUS +19.6%, $ISPR +19.1%. $HOMB and $SUI volumes doubled. $BTF +343% in two weeks; $CRVS, $MOVE, $BOIL 3-digit gains. $USAX, $MSCLF +65% with outsized volume, multiday strength.
February 3, 2026 at 3:05 PM
Feb 3 screen showed bullish expansion across trend and SMA crossovers. In 50-200 SMA $SJ +21.8% vol +114%, $CBUS +19.6%, $ISPR +19.1%. $HOMB and $SUI volumes doubled. $BTF +343% in two weeks; $CRVS, $MOVE, $BOIL 3-digit gains. $USAX, $MSCLF +65% with outsized volume, multiday strength.
Commit To Buy Corvus Pharmaceuticals At $8, Earn 20% Using Options
Investors considering a purchase of Corvus Pharmaceuticals Inc (Symbol: CRVS) stock, but tentative about paying the going market price of $21.47/share, might benefit from considering selling puts among the alternative strategies at…
Investors considering a purchase of Corvus Pharmaceuticals Inc (Symbol: CRVS) stock, but tentative about paying the going market price of $21.47/share, might benefit from considering selling puts among the alternative strategies at…
Commit To Buy Corvus Pharmaceuticals At $8, Earn 20% Using Options
Investors considering a purchase of Corvus Pharmaceuticals Inc (Symbol: CRVS) stock, but tentative about paying the going market price of $21.47/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2028 put at the $8 strike, which has a bid at the time of this writing of $1.60.
stockupdatesnow.com
February 2, 2026 at 5:19 PM
Commit To Buy Corvus Pharmaceuticals At $8, Earn 20% Using Options
Investors considering a purchase of Corvus Pharmaceuticals Inc (Symbol: CRVS) stock, but tentative about paying the going market price of $21.47/share, might benefit from considering selling puts among the alternative strategies at…
Investors considering a purchase of Corvus Pharmaceuticals Inc (Symbol: CRVS) stock, but tentative about paying the going market price of $21.47/share, might benefit from considering selling puts among the alternative strategies at…
where are all the other furries driving crvs
🫵🏻👁️ show me
🫵🏻👁️ show me
February 1, 2026 at 3:34 AM
where are all the other furries driving crvs
🫵🏻👁️ show me
🫵🏻👁️ show me
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) Sees Significant Price Target Increase and Stock Surge www.stocks2buy.net/newsitems/co...
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) Sees Significant Price Target Increase and Stock Surge
Graig Suvannavejh from Mizuho Securities set a new price target of $30 for CRVS, indicating a potential 46.06% increase. CRVS stock has experienced a 209% surge following positive Phase I study…
www.stocks2buy.net
January 30, 2026 at 2:26 AM
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) Sees Significant Price Target Increase and Stock Surge www.stocks2buy.net/newsitems/co...
January 30, 2026 at 1:01 AM
yall can have fun, no way crvs ever buying a game for 60 again
Tomodachi Life: Living the Dream up for preorder on US eShop ($59.99) buff.ly/xxMgCBg
January 29, 2026 at 5:08 PM
yall can have fun, no way crvs ever buying a game for 60 again
Ford makes some cool ass cars, unfortunately they're known for shitty manufacturing. 😭 Hope you find something reliable and budget friendly! Mazda CX and CRVs ho hard for this in the SUV category
January 29, 2026 at 4:02 AM
Ford makes some cool ass cars, unfortunately they're known for shitty manufacturing. 😭 Hope you find something reliable and budget friendly! Mazda CX and CRVs ho hard for this in the SUV category
$CRVS files SCHEDULE 13D/A
OrbiMed's Stake in Corvus Pharmaceuticals Diluted to 10.3% Following Recent Public Offering...
Full: https://wiseek.ai/ticker/crvs/orbimed-s-stake-in-corvus-pharmaceuticals-diluted-to-10-3-following-recent-public-offering-000094787126000068/
OrbiMed's Stake in Corvus Pharmaceuticals Diluted to 10.3% Following Recent Public Offering...
Full: https://wiseek.ai/ticker/crvs/orbimed-s-stake-in-corvus-pharmaceuticals-diluted-to-10-3-following-recent-public-offering-000094787126000068/
January 28, 2026 at 6:48 AM
$CRVS files SCHEDULE 13D/A
OrbiMed's Stake in Corvus Pharmaceuticals Diluted to 10.3% Following Recent Public Offering...
Full: https://wiseek.ai/ticker/crvs/orbimed-s-stake-in-corvus-pharmaceuticals-diluted-to-10-3-following-recent-public-offering-000094787126000068/
OrbiMed's Stake in Corvus Pharmaceuticals Diluted to 10.3% Following Recent Public Offering...
Full: https://wiseek.ai/ticker/crvs/orbimed-s-stake-in-corvus-pharmaceuticals-diluted-to-10-3-following-recent-public-offering-000094787126000068/
Japan, even more so than the US, has had its head in the sand on EVs for a long time now. No sympathy as their auto industry does a painful correction.
They could have been selling electric CRVs and RAV4s like hotcakes the past decade but instead they falsely pushed hydrogen and solid state bs.
They could have been selling electric CRVs and RAV4s like hotcakes the past decade but instead they falsely pushed hydrogen and solid state bs.
January 28, 2026 at 2:01 AM
Japan, even more so than the US, has had its head in the sand on EVs for a long time now. No sympathy as their auto industry does a painful correction.
They could have been selling electric CRVs and RAV4s like hotcakes the past decade but instead they falsely pushed hydrogen and solid state bs.
They could have been selling electric CRVs and RAV4s like hotcakes the past decade but instead they falsely pushed hydrogen and solid state bs.
And not to blame the individuals too hard, but if I had subprime credit and a paralegal salary I would probably look for a different car.
$1100/mo on an SUV that has notoriously bad fuel economy and requires premium gas was probably not a wise financial move. CRVs aren't that bad!
$1100/mo on an SUV that has notoriously bad fuel economy and requires premium gas was probably not a wise financial move. CRVs aren't that bad!
January 27, 2026 at 7:57 PM
And not to blame the individuals too hard, but if I had subprime credit and a paralegal salary I would probably look for a different car.
$1100/mo on an SUV that has notoriously bad fuel economy and requires premium gas was probably not a wise financial move. CRVs aren't that bad!
$1100/mo on an SUV that has notoriously bad fuel economy and requires premium gas was probably not a wise financial move. CRVs aren't that bad!
fuck it crvs voting Republican from now on
January 27, 2026 at 3:41 PM
fuck it crvs voting Republican from now on
Freedom Broker named the best and worst Russell 2000 performers from Jan 9–22: #$CRVS surged on positive trial data for its atopic dermatitis drug, while #$TSE lagged on falling revenue, rising losses, and heavy debt 👇 en.oninvest.com/article/free...
Freedom names biggest small-cap winner and loser in last two weeks – Oninvest
Freedom Broker has named the two stocks from the smid-cap-tracking Russell 2000 index with best and worst performance from January 9 through January 22. The former was recorded by Corvus Pharmaceutica...
en.oninvest.com
January 26, 2026 at 7:15 PM
Freedom Broker named the best and worst Russell 2000 performers from Jan 9–22: #$CRVS surged on positive trial data for its atopic dermatitis drug, while #$TSE lagged on falling revenue, rising losses, and heavy debt 👇 en.oninvest.com/article/free...
Freedom Broker named the best and worst Russell 2000 performers from Jan 9–22: #$CRVS surged on positive trial data for its atopic dermatitis drug, while #$TSE lagged on falling revenue, rising losses, and heavy debt 👇 en.oninvest.com/article/free...
Freedom names biggest small-cap winner and loser in last two weeks – Oninvest
Freedom Broker has named the two stocks from the smid-cap-tracking Russell 2000 index with best and worst performance from January 9 through January 22. The former was recorded by Corvus Pharmaceutica...
en.oninvest.com
January 26, 2026 at 7:14 PM
Freedom Broker named the best and worst Russell 2000 performers from Jan 9–22: #$CRVS surged on positive trial data for its atopic dermatitis drug, while #$TSE lagged on falling revenue, rising losses, and heavy debt 👇 en.oninvest.com/article/free...
#BiotechHangout Grace Colon, Tim Opler, Graig Suvannavejh, Eric Schmidt on biopharma market outlook & sentiment, bull/bear debate, IPOs, deals: #$GSK / #$RAPT, #$JANX / #$BMY, policy: US exits WHO, NDAA bill updates for biotech, FDA myeloma guidelines, & #$CRVS data & women’s health report bit.ly/4r3fGlY
January 23, 2026 at 3:59 PM
#BiotechHangout Grace Colon, Tim Opler, Graig Suvannavejh, Eric Schmidt on biopharma market outlook & sentiment, bull/bear debate, IPOs, deals: #$GSK / #$RAPT, #$JANX / #$BMY, policy: US exits WHO, NDAA bill updates for biotech, FDA myeloma guidelines, & #$CRVS data & women’s health report bit.ly/4r3fGlY
January 22, 2026 at 11:01 PM
Here's a quick and dirty list of the best performing stocks this year with a market cap over $100M
January 22, 2026 at 7:19 PM
Here's a quick and dirty list of the best performing stocks this year with a market cap over $100M
Smalls are leading in 2026.
Inspired by Oliver Kell’s momentum framework, this scan surfaces Russell 2000 names that already doubled and are still holding strength.
Top performers last 30D:
$CRVS $ALMS $SKYT $METC $UUUU $UEC $VICR $GLUE
Inspired by Oliver Kell’s momentum framework, this scan surfaces Russell 2000 names that already doubled and are still holding strength.
Top performers last 30D:
$CRVS $ALMS $SKYT $METC $UUUU $UEC $VICR $GLUE
January 22, 2026 at 7:10 PM
Smalls are leading in 2026.
Inspired by Oliver Kell’s momentum framework, this scan surfaces Russell 2000 names that already doubled and are still holding strength.
Top performers last 30D:
$CRVS $ALMS $SKYT $METC $UUUU $UEC $VICR $GLUE
Inspired by Oliver Kell’s momentum framework, this scan surfaces Russell 2000 names that already doubled and are still holding strength.
Top performers last 30D:
$CRVS $ALMS $SKYT $METC $UUUU $UEC $VICR $GLUE
#CRVS Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
https://www.stocktitan.net/news/CRVS/corvus-pharmaceuticals-announces-pricing-of-upsized-public-offering-tmspim5sajoj.html
https://www.stocktitan.net/news/CRVS/corvus-pharmaceuticals-announces-pricing-of-upsized-public-offering-tmspim5sajoj.html
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 7,900,677 shares of its common stock at a price to the public of $22.15
www.stocktitan.net
January 22, 2026 at 3:54 AM
#CRVS Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
https://www.stocktitan.net/news/CRVS/corvus-pharmaceuticals-announces-pricing-of-upsized-public-offering-tmspim5sajoj.html
https://www.stocktitan.net/news/CRVS/corvus-pharmaceuticals-announces-pricing-of-upsized-public-offering-tmspim5sajoj.html
January 22, 2026 at 2:01 AM
Viet Nam has signed the National Action Program on CRVS for 2026-2030, a landmark commitment to a #CRVS system #CountingEveryone with @unfpa.org.
Learn more about #TheLifesavingPotentialOfDeathData and the @bloombergdotorg.bsky.social #Data4Health Initiative: https://vitalstrat.org/4b7h2rj
Learn more about #TheLifesavingPotentialOfDeathData and the @bloombergdotorg.bsky.social #Data4Health Initiative: https://vitalstrat.org/4b7h2rj
January 21, 2026 at 9:09 PM
Viet Nam has signed the National Action Program on CRVS for 2026-2030, a landmark commitment to a #CRVS system #CountingEveryone with @unfpa.org.
Learn more about #TheLifesavingPotentialOfDeathData and the @bloombergdotorg.bsky.social #Data4Health Initiative: https://vitalstrat.org/4b7h2rj
Learn more about #TheLifesavingPotentialOfDeathData and the @bloombergdotorg.bsky.social #Data4Health Initiative: https://vitalstrat.org/4b7h2rj
Corvus challenger to Dupixent, JAKs gains ground in early atopic dermatitis study $CRVS $SNY $REGN firstwordpharma.com/story/7072257
January 20, 2026 at 11:14 PM
Corvus challenger to Dupixent, JAKs gains ground in early atopic dermatitis study $CRVS $SNY $REGN firstwordpharma.com/story/7072257
Most searched small-cap stocks, Tue Jan 20th - #$UWMC #$OGN #$BTBT #$RDW #$RAPT #$ACRS #$TE #$RR #$BITF #$TWG #$DNN #$RZLV #$PLUG #$BBAI #$USAR #$UAMY #$KTOS #$JMIA #$HYMC #$CRVS - More: crystalequityresearch.com/most-searche... - #smallcap
Most Searched, Tuesday January 20, 2026 – Crystal Equity Research
crystalequityresearch.com
January 20, 2026 at 10:24 PM
$CRVS soquelitinib Phase 1 in atopic dermatitis: 75% EASI 75, 25% EASI 90, 33% IGA 0/1 at 8 weeks. #biotech
www.biopharmcatalyst.com/news/2026/co...
www.biopharmcatalyst.com/news/2026/co...
Daily Updates 01/20/26
export-download.canva.com
January 20, 2026 at 9:30 PM
$CRVS soquelitinib Phase 1 in atopic dermatitis: 75% EASI 75, 25% EASI 90, 33% IGA 0/1 at 8 weeks. #biotech
www.biopharmcatalyst.com/news/2026/co...
www.biopharmcatalyst.com/news/2026/co...